Over the past decade, immune checkpoint inhibitors (ICIs) targeting PD-1, PD-L1, and CTLA-4 have become key treatments for many solid cancers, including hepatocellular carcinoma (HCC). This evidence concerns the gene CTLA4 and hepatocellular carcinoma.